본문으로 건너뛰기
← 뒤로

Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.

1/5 보강
Nature communications 2024 Vol.15(1) p. 3175
Retraction 확인
출처

Qu N, Chen D, Ma B, Zhang L, Wang Q, Wang Y, Wang H, Ni Z, Wang W, Liao T, Xiang J, Wang Y, Jin S, Xue D, Wu W, Wang Y, Ji Q, He H, Piao HL, Shi R

📝 환자 설명용 한 줄

Although papillary thyroid cancer (PTC) has a good prognosis, its recurrence rate is high and remains a core concern in the clinic.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Qu N, Chen D, et al. (2024). Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.. Nature communications, 15(1), 3175. https://doi.org/10.1038/s41467-024-47581-1
MLA Qu N, et al.. "Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.." Nature communications, vol. 15, no. 1, 2024, pp. 3175.
PMID 38609408

Abstract

Although papillary thyroid cancer (PTC) has a good prognosis, its recurrence rate is high and remains a core concern in the clinic. Molecular factors contributing to different recurrence risks (RRs) remain poorly defined. Here, we perform an integrative proteogenomic and metabolomic characterization of 102 Chinese PTC patients with different RRs. Genomic profiling reveals that mutations in MUC16 and TERT promoter as well as multiple gene fusions like NCOA4-RET are enriched by the high RR. Integrative multi-omics analyses further describe the multi-dimensional characteristics of PTC, especially in metabolism pathways, and delineate dominated molecular patterns of different RRs. Moreover, the PTC patients are clustered into four subtypes (CS1: low RR and BRAF-like; CS2: high RR and metabolism type, worst prognosis; CS3: high RR and immune type, better prognosis; CS4: high RR and BRAF-like) based on the omics data. Notably, the subtypes display significant differences considering BRAF and TERT promoter mutations, metabolism and immune pathway profiles, epithelial cell compositions, and various clinical factors (especially RRs and prognosis) as well as druggable targets. This study can provide insights into the complex molecular characteristics of PTC recurrences and help promote early diagnosis and precision treatment of recurrent PTC.

MeSH Terms

Humans; Thyroid Cancer, Papillary; Proteogenomics; Proto-Oncogene Proteins B-raf; Metabolomics; Thyroid Neoplasms

같은 제1저자의 인용 많은 논문 (4)